Oncolytic adenoviruses: A thorny path to glioma cure.

Abstract

Glioblastoma Multiforme (GBM) is a rapidly progressing brain tumor. Despite the relatively low percentage of cancer patients with glioma diagnoses, recent statistics indicate that the number of glioma patients may have increased over the past decade. Current therapeutic options for glioma patients include tumor resection, chemotherapy, and concomitant radiation therapy with an average survival of approximately 16 months. The rapid progression of gliomas has spurred the development of novel treatment options, such as cancer gene therapy and oncolytic virotherapy. Preclinical testing of oncolytic adenoviruses using glioma models revealed both positive and negative sides of the virotherapy approach. Here we present a detailed overview of the glioma virotherapy field and discuss auxiliary therapeutic strategies with the potential for augmenting clinical efficacy of GBM virotherapy treatment.

• Authors: I V Ulasov, A V Borovjagin, B A Schroeder, A Y Baryshnikov
• Journal: Genes & diseases (Genes Dis) Vol. 1 Issue 2 Pg. 214-226 (Dec 2014) ISSN: 2352-4820 [Print] China
• PMID: 25685829 (Publication Type: Journal Article)